Tysabri Taking Biogen Idec To New Highs Forbes Founded in 1985, Biogen has several candidates in its pipeline, including BG-12 (multiple sclerosis), daclizumab (multiple sclerosis), Factor VIII (hemophilia A) and Factor IX (hemophilia B) among others. Solid Second Quarter Results. On July 24 ... Biogen Idec - Momentum |
